Simvastatin: present and future perspectives

Bibliography

• STRONG K, MATHERS C, LEEDER S, BEAGLEHOLE R: Preventing chronic diseases: how many lives can we save? Lancet (2005) 366:1578-1582.
   PubMed Web of Science ®Google Scholar
• THOM T, HAASE N, ROSAMOND W et al.: Heart disease and stroke statistics – 2006 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation (2006) 113:E85-E151.
   PubMed Web of Science ®Google Scholar
• SHOOB HD, CROFT JB, LABARTHE DR: Impact of baby boomers on hospitalizations for coronary heart disease and stroke in the United States. Prev. Med. (2007) 44:447-451.
   PubMed Web of Science ®Google Scholar
• ROTHWELL P, COULL A, SILVER L et al.: Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study) Lancet (2005) 366:1773-1783.
   PubMed Web of Science ®Google Scholar
• CHOLESTEROL TREATMENT TRIALISTS' (CTT) COLLABORATORS: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 366:1267-1278.
   PubMed Web of Science ®Google Scholar
• NATIONAL CHOLESTEROL EDUCATION PANEL: Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment Panel III) final report. Circulation (2002) 106:3143-3421.
   PubMed Web of Science ®Google Scholar
• DE BACKER G, AMBROSIONI E, BORCH-JOHNSEN K et al.: European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur. J. Cardiovasc. Prev. Rehab. (2003) 10:S1-S78.
   Google Scholar
• GENEST J, FROHLICH J, FODOR G, MCPHERSON R: Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ (2003) 169:921-924.
   PubMed Web of Science ®Google Scholar
• CANNON CP, STEINBERG BA, MURPHY SA et al.: Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J. Am. Coll. Cardiol. (2006) 48:438-445.
   PubMed Web of Science ®Google Scholar
• GRUNDY SM, CLEEMAN JI, MERZ CNB et al.: Implications of recent clinical trials for the National cholesterol education program adult treatment Panel III guidelines. Circulation (2004) 110:227-239.
   PubMed Web of Science ®Google Scholar
• SMITH JSC, ALLEN J, BLAIR SN et al.: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National heart, lung, and blood Institute. J. Am. Coll. Cardiol. (2006) 47:2130-2139.
   PubMed Web of Science ®Google Scholar
• NASH DB, NASH SA: Reclassification of simvastatin to over-the-counter status in the United Kingdom: a primary prevention strategy. Am. J. Cardiol. (2004) 94:35-39.
   PubMed Web of Science ®Google Scholar
• HOFFMAN WF, ALBERTS AW, ANDERSON PS et al.: 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side-chain ester derivatives of mevinolin. J. Med. Chem. (1986) 29:849-852.
   PubMed Web of Science ®Google Scholar
• GRUNDY S: HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N. Engl. J. Med. (1988) 319:24-33.
   PubMed Web of Science ®Google Scholar
• BILHEIMER DW, GRUNDY SM, BROWN MS, GOLDSTEIN JL: Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. Atherosclerosis Suppl. (2004) 5:61-65.
   PubMedGoogle Scholar
• BROWN M, GOLDSTEIN J: Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. J. Clin. Invest. (1983) 72:743-747.
   PubMed Web of Science ®Google Scholar
• PRUEKSARITANONT T, GORHAM LM, MA B et al.: In vitro metabolism of simvastatin in humans [sbt]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab. Dispos. (1997) 25:1191-1199.
   PubMed Web of Science ®Google Scholar
• PRUEKSARITANONT T, SUBRAMANIAN R, FANG X et al.: Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Dispos. (2002) 30:505-512.
   PubMed Web of Science ®Google Scholar
• GOOSEN TC, BAUMAN JN, DAVIS JA et al.: Atorvastatin glucuronidation is minimally and non-selectively inhibited by the fibrates gemfibrozil, fenofibrate and fenofibric acid. Drug Metab. Dispos. (2007) 35(8):1315-1324.
   PubMed Web of Science ®Google Scholar
• SPENCE J, MUNOZ C, HENDRICKS L et al.: Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am. J. Cardiol. (1995) 76:A80-A83.
   Web of Science ®Google Scholar
• PRUEKSARITANONT T, TANG C, QIU Y et al.: Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos. (2002) 30:1280-1287.
   PubMed Web of Science ®Google Scholar
• KIM K-A, PARK P-W, LEE O-J et al.: Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J. Clin. Pharmacol. (2007) 47:87-93.
   PubMed Web of Science ®Google Scholar
• PASANEN M, NEUVONEN M, NEUVONEN P, NIEMI M: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genom. (2006) 16:873-879.
   PubMed Web of Science ®Google Scholar
• VICKERS S, DUNCAN CA, VYAS KP et al.: In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab. Dispos. (1990) 18:476-483.
   PubMed Web of Science ®Google Scholar
• WALLACE A, CHINN D, RUBIN G: Taking simvastatin in the morning compared with in the evening: randomised controlled trial. BMJ (2003) 327:788.
   PubMed Web of Science ®Google Scholar
• CHENG H, ROGERS J, SWEANY A et al.: Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm. Res. (1992) 9:1629-1633.
   PubMed Web of Science ®Google Scholar
• HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360:7-22.
   PubMed Web of Science ®Google Scholar
• BALLANTYNE CM, BLAZING MA, HUNNINGHAKE DB et al.: Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the comparative HDL efficacy and safety study (CHESS). Am. Heart J. (2003) 146:862-869.
   PubMed Web of Science ®Google Scholar
• ROGERS SL, MAGLIANO DJ, LEVISON DB et al.: A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clin. Ther. (2007) 29:242-252.
   PubMed Web of Science ®Google Scholar
• SIMOONS ML, SAELMAN JPM: Effect of simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS). Lancet (1994) 344:633-638.
   PubMed Web of Science ®Google Scholar
• BROWN BG, ZHAO X-Q, CHAIT A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. (2001) 345:1583-1592.
   PubMed Web of Science ®Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY G: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383-1389.
   PubMed Web of Science ®Google Scholar
• PEDERSEN TR: Coronary artery disease: the Scandinavian Simvastatin Survival Study Experience. Am. J. Cardiol. (1998) 82:53-56.
   PubMed Web of Science ®Google Scholar
• PYORALA K, PEDERSEN TR, KJEKSHUS J et al.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care (1997) 20:614-620.
   PubMed Web of Science ®Google Scholar
• MIETTINEN TA, PYORALA K, OLSSON AG et al.: Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation (1997) 96:4211-4218.
   PubMed Web of Science ®Google Scholar
• PYORALA K, BALLANTYNE CM, GUMBINER B et al.: Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care (2004) 27:1735-1740.
   PubMed Web of Science ®Google Scholar
• HEART PROTECTION STUDY COLLABORATIVE G: The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med. (2005) 3:6.
   PubMedGoogle Scholar
• HEART PROTECTION STUDY COLLABORATIVE GROUP: Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J. Vasc. Surg. (2007) 45:645-654; discussion 653-654.
   PubMed Web of Science ®Google Scholar
• HEART PROTECTION STUDY COLLABORATIVE G: N-terminal pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J. Am. Coll. Cardiol. (2007) 49:311-319.
   Google Scholar
• HEART PROTECTION STUDY COLLABORATIVE GROUP: Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk complications. Lancet (2004) 363:757-767.
   Google Scholar
• HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (2003) 361:2005-2016.
   Google Scholar
• MACMAHON M, KIRKPATRICK C, CUMMINGS C et al.: A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH). Nutr. Metab. Cardiovasc. Dis. (2000) 10:195-203.
   PubMed Web of Science ®Google Scholar
• PACKARD C: Improving outcomes through statin therapy – a review of ongoing trials. Eur. Heart J. Suppl. (2004) 6:A28-A31.
   Web of Science ®Google Scholar
• ROBINSON J, DAVIDSON M: Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev. Cardiovasc. Ther. (2006) 4:461-476.
   PubMedGoogle Scholar
• BALLANTYNE CM, ABATE N, YUAN Z et al.: Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the vytorin versus atorvastatin (VYVA) study. Am. Heart J. (2005) 149:464-473.
   PubMed Web of Science ®Google Scholar
• CATAPANO AL, DAVIDSON MH, BALLANTYNE CM et al.: Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients Curr. Med. Res. Opin (2006) 22:2041-2053.
   PubMed Web of Science ®Google Scholar
• DAVIDSON MH, MACCUBBIN D, STEPANAVAGE M et al.: Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am. J. Cardiol. (2006) 97:223-228.
   PubMed Web of Science ®Google Scholar
• ROSSEBO AB, PEDERSEN TR, ALLEN C et al.: Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am. J. Cardiol. (2007) 99:970-973.
   PubMed Web of Science ®Google Scholar
• BAIGENT C, LANDRY M: Study of heart and renal protection (SHARP). Kidney Int. (2003) 63:S207-S210.
   Web of Science ®Google Scholar
• WOLFE ML, VARTANIAN SF, ROSS JL et al.: Safety and effectiveness of niaspan when added sequentially to a statin for treatment of dyslipidemia. Am. J. Cardiol. (2001) 87:476-479.
   PubMed Web of Science ®Google Scholar
• MEYERS CD, LIU P, KAMANNA VS, KASHYAP ML: Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush. Atherosclerosis (2007) 192:253-258.
   PubMed Web of Science ®Google Scholar
• CHENG K, WU T-J, WU KK et al.: Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl. Acad. Sci. USA (2006) 103:6682-6687.
   PubMed Web of Science ®Google Scholar
• MCGOVERN M: Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome. Br. J. Diabetes Vasc. Dis. (2004) 4:78-85.
   Google Scholar
• CANNER PL, FURBERG CD, MCGOVERN ME: Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am. J. Cardiol. (2006) 97:477-479.
   PubMed Web of Science ®Google Scholar
• ALSHEIKH-ALI AA, KARAS RH: Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States food and drug administration adverse event reporting system). Am. J. Cardiol. (2007) 99:379-381.
   PubMed Web of Science ®Google Scholar
• GUYTON JR, BAYS HE: Safety considerations with niacin therapy. Am. J. Cardiol. (2007) 99:S22-S31.
   PubMed Web of Science ®Google Scholar
• THOMPSON PD, CLARKSON PM, ROSENSON RS: An assessment of statin safety by muscle experts. Am. J. Cardiol. (2006) 97:S69-S76.
   PubMed Web of Science ®Google Scholar
• GRAHAM DJ, STAFFA JA, SHATIN D et al.: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA (2004) 292:2585-2590.
   PubMed Web of Science ®Google Scholar
• KANTOLA T, KIVISTO KT, NEUVONEN PJ: Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. (1998) 64:177-182.
   PubMed Web of Science ®Google Scholar
• JACOBSON TA: Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am. J. Cardiol. (2004) 94:1140-1146.
   PubMed Web of Science ®Google Scholar
• NEUVONEN PJ, NIEMI M, BACKMAN JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. (2006) 80:565-581.
   PubMed Web of Science ®Google Scholar
• MOLDEN E, ANDERSSON K: Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. Pharmacotherapy (2007) 27:603-607.
   PubMed Web of Science ®Google Scholar
• RICAURTE B, GUIRGUIS A, TAYLOR HC, ZABRISKIE D: Simvastatin–amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann. Pharmacother. (2006) 40:753-757.
   PubMed Web of Science ®Google Scholar
• JACOB SS, JACOB S, WILLIAMS C, DEEG MA: Simvastatin, fenofibrate, and rhabdomyolysis. Diabetes Care (2005) 28:1258.
   PubMed Web of Science ®Google Scholar
• MORO H, TSUKADA H, TANUMA A et al.: Rhabdomyolysis after simvastatin therapy in an HIV-infected patient with chronic renal failure. AIDS Patient Care STDS (2004) 18:687-690.
   PubMed Web of Science ®Google Scholar
• ROTEN L, SCHOENENBERGER RA, KRAHENBUHL S, SCHLIENGER RG: Rhabdomyolysis in association with simvastatin and amiodarone. Ann. Pharmacother. (2004) 38:978-981.
   PubMed Web of Science ®Google Scholar
• ANDREOU E, LEDGER S: Potential drug interaction between simvastatin and danazol causing rhabdomyolysis. Can. J. Clin. Pharmacol. (2003) 10:172-174.
   PubMedGoogle Scholar
• HARE C, VU M, GRUNFELD C, LAMPIRIS H: Simvastatin–nelfinavir interaction implicated in rhabdomyolysis and death. Clin. Infect. Dis. (2002) 35:E111-E112.
   PubMed Web of Science ®Google Scholar
• CHENG CH, MILLER C, LOWE C, PEARSON VE: Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am. J. Health Syst. Pharm. (2002) 59:728-730.
   PubMed Web of Science ®Google Scholar
• PECES R, POBES A: Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron (2001) 89:117-118.
   PubMed Web of Science ®Google Scholar
• ARNADOTTIR M, ERIKSSON L, THYSELL H, KARKAS J: Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron (1993) 65:410-413.
   PubMed Web of Science ®Google Scholar
• VAN PUIJENBROEK E, DU BUF-VEREIJKEN P, SPOOREN P, VAN DOORMAAL J: Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J. Intern. Med. (1996) 240:403-404.
   PubMed Web of Science ®Google Scholar
• DREIER JP, ENDRES M: Statin-associated rhabdomyolysis triggered by grapefruit consumption. Neurology (2004) 62:670.
   PubMed Web of Science ®Google Scholar
• SCHMASSMANN-SUHIJAR D, BULLINGHAM R, GASSER R et al.: Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet (1998) 351:1929-1930.
   PubMed Web of Science ®Google Scholar
• BOTTORFF MB: Statin safety and drug interactions: clinical implications. Am. J. Cardiol. (2006) 97:S27-S31.
   PubMed Web of Science ®Google Scholar
• BECQUEMONT L, NEUVONEN M, VERSTUYFT C et al.: Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin. Pharmacol. Ther. (2007) 81:679-684.
   PubMed Web of Science ®Google Scholar
• PRUEKSARITANONT T, ZHAO JJ, MA B et al.: Mechanistic studies on metabolic interactions between gemfibrozil and statins. J. Pharmacol. Exp. Ther. (2002) 301:1042-1051.
   PubMed Web of Science ®Google Scholar
• KARNIK NS, MALDONADO JR: Antidepressant and statin Interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. Psychosomatics (2005) 46:565-568.
   PubMed Web of Science ®Google Scholar
• WEBBER MA, MAHMUD W, LIGHTFOOT JD, SHEKHAR A: Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. J. Psychopharmacol. (2004) 18:432-434.
   PubMed Web of Science ®Google Scholar
• THE DAD STUDY GROUP: Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. (2007) 356:1723-1735.
   Google Scholar
• BELLOSTA S, PAOLETTI R, CORSINI A: Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation (2004) 109:III-50-57.
   PubMedGoogle Scholar
• NEUVONEN P, KANTOLA T, KIVISTO K: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. (1998) 63:332-341.
   PubMed Web of Science ®Google Scholar
• LILJA JJ, NEUVONEN M, NEUVONEN PJ: Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br. J. Clin. Pharmacol. (2004) 58:56-60.
   PubMed Web of Science ®Google Scholar
• LILJA JJ, KIVISTO KT, NEUVONEN PJ: Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin[ast]. Clin. Pharmacol. Ther. (2000) 68:384-390.
   PubMed Web of Science ®Google Scholar
• LILJA J, KIVISTO K, NEUVONEN P: Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin. Pharmacol. Ther. (1998) 64:477-483.
   PubMed Web of Science ®Google Scholar
• EDWARDS DJ, BERNIER SM: Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci. (1996) 59:1025-1030.
   PubMed Web of Science ®Google Scholar
• TRANSON C, LEEMANN T, DAYER P: In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur. J. Clin. Pharmacol. (1996) 50:209-215.
   PubMed Web of Science ®Google Scholar
• COHEN D, ANANIA F, CHALASANI N: An assessment of statin safety by hepatologists. Am. J. Cardiol. (2006) 97:S77-S81.
   PubMed Web of Science ®Google Scholar
• DAVIDSON M, ROBINSON JG: Safety of aggressive lipid management. J. Am. Coll. Cardiol. (2007) 49:1753-1762.
   PubMed Web of Science ®Google Scholar
• BRASS LM, ALBERTS MJ, SPARKS L: An assessment of statin safety by neurologists. Am. J. Cardiol. (2006) 97:S86-S88.
   PubMed Web of Science ®Google Scholar
• KASISKE BL, WANNER C, O'NEILL WC: An assessment of statin safety by nephrologists. Am. J. Cardiol. (2006) 97:S82-S85.
   PubMed Web of Science ®Google Scholar
• JACOBSON TA: Statin safety: lessons from new drug applications for marketed statins. Am. J. Cardiol. (2006) 97:S44-S51.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, VIDT D, MILLER E et al.: Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology (2007) 107:433-443.
   PubMed Web of Science ®Google Scholar
• DOUGLAS K, O'MALLEY PG, JACKSON JL: Meta-analysis: the effect of statins on albuminuria. Ann. Intern. Med. (2006) 145:117-124.
   PubMed Web of Science ®Google Scholar
• DALE KM, COLEMAN CI, HENYAN NN et al.: Statins and cancer risk: a meta-analysis. JAMA (2006) 295:74-80.
   PubMed Web of Science ®Google Scholar
• STRANDBERG T, PYORALA K, COOK TJ et al.: Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet (2004) 364:771-777.
   PubMed Web of Science ®Google Scholar
• BULBULIA R, BOWMAN L, WALLENDAZUS K et al.: MRC/BHF heart protection study (HPS): mortality, cancer incidence and major vascular evetns during 4 years post-trial follow-up of HPS [abstract] Presented at the American College of Cardiology 56th Annual Scientific Session. J. Am. Coll. Cardiol. (2007) 49:A394A.
   Google Scholar
• CHAN PS, NALLAMOTHU BK, GURM HS et al.: Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation (2007) 115:2398-2409.
   PubMed Web of Science ®Google Scholar
• HEART PROTECTION STUDY COLLABORATIVE GROUP: Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ (2006) 333:1145. doi:10.1136/bmj.38993.731725.BE
   Google Scholar
• ROBINSON JG, STONE NJ: Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am. J. Cardiol. (2006) 98:1405-1408.
   PubMed Web of Science ®Google Scholar
• TALL AR, YVAN-CHARVET L, WANG N: The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler. Thromb. Vasc. Biol. (2007) 27:257-260.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, TARDIF J-C, NICHOLLS SJ et al.: Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. (2007) 356:1304-1316.
   PubMed Web of Science ®Google Scholar
• KASTELEIN JJP, VAN LEUVEN SI, BURGESS L et al.: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. (2007) 352:1425-1435.
   Web of Science ®Google Scholar
• ROBINSON JG, MAHESHWARI N: A “poly-portfolio” for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. Am. J. Cardiol. (2005) 95:373-378.
   PubMed Web of Science ®Google Scholar
• HOLMES HM, HAYLEY DC, ALEXANDER GC, SACHS GA: Reconsidering medication appropriateness for patients late in life. Arch. Intern. Med. (2006) 166:605-609.
   PubMedGoogle Scholar
• ROBINSON JG, BAKRIS G, TORNER J et al.: Is it time for a cardiovascular primary prevention trial in the elderly? Stroke (2007) 38:441-450.
   PubMed Web of Science ®Google Scholar
• GORELICK PB: Uncertainty of management of blood pressure and lipids in the elderly: time for a primary prevention trial. Stroke (2007) 38:212-213.
   PubMed Web of Science ®Google Scholar
• BROOKHART MA, PATRICK AR, SCHNEEWEISS S et al.: Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch. Intern. Med. (2007) 167:847-852.
   PubMed Web of Science ®Google Scholar